TTrialPathMatch Me to Trials
← Back to trials
RecruitingPancreatic Ductal Adenocarcinoma (PDAC)G12D Mutated KRAS

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

Eligible age

18+ yrs

Accepts

All genders

Locations

17 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer

Sponsor: Verastem, Inc.

You may qualify if…

  • ✓ Histologic or cytologic confirmed PDAC
  • ✓ Measurable disease per RECIST 1.1
  • ✓ Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)
  • ✓ ECOG PS=0 or 1
  • ✓ Adequate organ function
  • ✓ VS-7375 + cetuximab (2L PDAC) :
  • ✓ Received only 1 prior Tx in the metastatic setting; prior adjuvant counts as a line if progressed within 6 months
  • ✓ VS-7375 + cetuximab (1L PDAC) :

You may not qualify if…

  • ✕ Have any documented co-existing pathogenic or likely pathogenic RAS mutation(s) in KRAS
  • ✕ Prior anti-cancer Tx within 4 weeks or drug-specific timeline within first treatment dose, whichever shorter
  • ✕ Major surgery within 4 weeks of first treatment dose
  • ✕ Radiation therapy (RT) within 1 week of first treatment dose; RT to brain or lung within 2 weeks of first treatment dose
  • ✕ History of drug-induced Interstitial Lung Disease
  • ✕ Receipt of prior direct RAS inhibitor
  • ✕ Untreated or symptomatic CNS metastasis
  • ✕ Receipt of strong CYP3A4 inhibitor/inducer or CYP3A4 sensitive substrates with narrow therapeutic index within 14 days or drug-specific timeline within first treatment dose, whichever is shorter

Where it's recruiting

California

Los Angeles

Florida

Coral Springs · Jacksonville · Tamarac · Tampa

Illinois

Chicago

Maryland

Baltimore

Michigan

Ann Arbor · Grand Rapids

Minnesota

Rochester

Missouri

St Louis

New Jersey

East Brunswick

New York

New York

North Carolina

Chapel Hill

Tennessee

Nashville

Source: ClinicalTrials.gov · NCT07644559 · last updated 2026-11-13